HBV Treatment
HBV Rebounds After Stopping Entecavir, Switching to Interferon May Help
- Details
- Category: HBV Treatment
- Published on Thursday, 10 July 2014 00:00
- Written by Liz Highleyman
Most hepatitis B "e" antigen (HBeAg) negative chronic hepatitis B patients relapsed after stopping treatment with the antiviral drug entecavir (Baraclude), according to a report in the May 15 online edition of Gut. A related study found that switching from entecavir to pegylated interferon increased the likelihood of HBeAg seroconversion and hepatitis B surface antigen(HBsAg) lossin HBeAg positive patients.
No Tenofovir Resistance Seen In 2 Years of Hepatitis B Treatment
- Details
- Category: Approved HBV Drugs
- Published on Friday, 27 June 2014 00:00
- Written by Liz Highleyman
No cases of resistance to tenofovir (Viread) were detected among chronic hepatitis B patients with prior resistance to lamivudine (3TC or Epivir) through 96 weeks of treatment, according to a study described in the June 11 advance edition of Clinical Gastroenterology and Hepatology. Adding emtricitabine (Emtriva) did not improve effectiveness compared with tenofovir alone.
DDW2014: Coverage of Digestive Disease Week 2014
- Details
- Category: HBV Treatment
- Published on Saturday, 31 May 2014 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 2014 Digestive Disease Week annual meeting (DDW 2014) in Chicago, May 3-6, 2014.
Hepatitis C
New Hepatitis C Treatments Highlighted at Digestive Disease Week
Some Negative Predictive Factors Do Not Impair Response to Faldaprevir
AbbVie Interferon-free Regimen Cures More than 90% of Hepatitis C Patients
Sustained Response to Interferon Is Durable in Children with Hepatitis C
HIV/HCV Coinfection
Some Negative Predictive Factors Do Not Impair Response to Faldaprevir
Hepatitis B
Outcomes in HBV/HCV Coinfected People Depend on Which Virus Dominates
Some Hepatitis B Patients Can Stop Antiviral Treatment Without Relapse
Complications and Related Conditions
Rifaximin May Be Beneficial for People with Advanced Liver Cirrhosis
Drinking More Coffee Is Associated with Less Liver Fibrosis
Antiviral Treatment for Hepatitis B Lowers Risk of Liver Cancer
- Details
- Category: HBV Treatment
- Published on Thursday, 19 June 2014 00:00
- Written by Liz Highleyman
Antiviral therapy for chronic hepatitis B virus (HBV) infection can reduce the risk of developing hepatocellular carcinoma (HCC), even among people with high HBV viral load, according to research described in the May 2014 edition of Clinical Gastroenterology and Hepatology.
DDW 2014: Some Hepatitis B Patients Can Stop Antiviral Treatment without Relapse
- Details
- Category: HBV Treatment
- Published on Tuesday, 06 May 2014 00:00
- Written by Liz Highleyman
Stopping antiviral therapy after several years appears generally safe for people with HBeAg negative chronic hepatitis B without liver cirrhosis, and a substantial proportion do not experience viral relapse or worsening liver inflammation while off treatment, according to a pair of posters presented at the Digestive Disease Week (DDW 2014) meeting this week in Chicago.
Web Design and Development by